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Introduction
Tobacco use in the US causes more than 480,000 fatalities each year, accounting for 
nearly one in five deaths.1,2 On a population level, tobacco cessation efforts have been 
complicated by the development of new alternative tobacco products, including elec-
tronic nicotine delivery systems (ENDS), which some smokers view as a method to help 
them quit smoking combustible cigarettes.3 In the US, use of ENDS, primarily electronic 
cigarettes (e-cigarettes), increased from 1.8% to 13% of the population between 2010 
and 2013.4 E-cigarettes consist of a battery, vaporizer, and nicotine solution; as the device 
heats the nicotine solution, it delivers an aerosol that the user inhales. Nicotine solu-
tion is usually packaged in a cartridge and is typically comprised of nicotine, propylene 
glycol, and flavoring agents (although the specific composition of nicotine solution can 
vary across different products and brands).5 Although ENDS were initially unregulated, 
in August 2016 the US Food and Drug Administration (FDA) made a deeming provision 
that subjected these products to federal regulation, which could include the creation of 
product quality standards and disclosure of the ingredients used in nicotine solutions.6,7
Although the health risks of combustible cigarettes are well known, research on the 
health risks of ENDS is ongoing.6-8 ENDS appear to generate lower levels of toxicants 
than combustible products that contain tobacco.8,9 However the US Centers for Disease 
Control and Prevention (CDC) reported that the aerosol generated by e-cigarettes is 
not harmless and not as safe as clean air.6 ENDS decompose the contents of nicotine 
solution during heating, potentially transforming them into toxic compounds that could 
pose health threats to the user.10 Safety concerns have also been raised about e-cigarette 
flavorings; although some have been considered safe for food consumption, little is 
known about the long-term effects of inhaling these substances into the lungs in aerosol 
form.6,11 The nicotine contained in ENDS is a highly addictive substance that can be 
detrimental to fetal brain development during pregnancy and to youth.6,7 Because the 
health effects of ENDS use are not well-understood, ENDS are not officially indicated 
for use as a smoking cessation aid.6 Studies comparing ENDS and traditional nicotine 
replacement therapy (NRT) for smoking cessation have found inconsistent results.3 
Despite the lack of definitive data to prove their efficacy, ENDS are marketed as safer 
alternatives to combustible cigarettes.6
Pharmacists are uniquely well-situated to promote smoking cessation due to their daily 
interactions with the public.12-14 In California, the scope of pharmacy practice expanded 
with the passage of SB 493 in 2013, which allows pharmacists to furnish prescription NRT 
and other medications that can help smokers quit, and the passage AB 1114 in 2016, which 
allows pharmacists to be reimbursed under Medi-Cal for furnishing medications.15-18 In 
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the US, both NRT and ENDS are avail-
able over the counter at many community 
pharmacies and may be sold in close 
proximity. Pharmacists, particularly 
community pharmacists, can initiate 
smoking cessation counseling and NRT 
use and provide patients with accurate 
information about the safety and use of 
ENDS.4,16 However, there is limited data 
regarding pharmacists’ knowledge and 
perceptions regarding ENDS, their health 
risks, and their potential role in cessation. 
This study sought to assess California 
pharmacists’ awareness and approaches 
regarding ENDS to gain insight into 
what information is offered to patients, 
and to determine whether there is 
a need for continuing professional 
education about ENDS targeted to 
pharmacists. We hypothesized that 
pharmacists would be aware of the 
regulatory status of ENDS and that 
their recommendations regarding cessa-
tion would be consistent with CDC 
guidelines, which state that “evidence is 
insufficient to recommend e-cigarettes 
for smoking cessation in adults.”19 
Methods 
To assess pharmacist knowledge and 
attitudes toward ENDS, we conducted 
an online, cross-sectional, exploratory 
survey of California pharmacists. Eligible 
respondents were California-licensed 
pharmacists with no exclusions based 
on area or years of practice. We received 
institutional review board approval on 
June 15, 2016 (redacted #16-19851), and 
began disseminating the survey via email 
to licensed pharmacists affiliated with 
California Pharmacy Student Leader-
ship, California schools of pharmacy, 
the California Society of Health-System 
Pharmacists (CSHP) listserv, and the 
American Society of Health System 
Pharmacists’ (ASHP) residency direc-
tory. Each potential participant received 
a single email, and respondents were 
self-selected. The survey was fielded 
between June 22 and August 6, 2016. The 
FDA changed its regulatory stance on 
e-cigarettes as of August 8, 2016, at which 
point the survey was closed.  
The survey was created using Qual-
trics software and housed on the UCSF 
Research Electronic Data Capture system, 
which provides secure and Health Insur-
ance Portability and Accountability Act of 
1996 compliant data storage and anony-
mized the survey responses. Our 17-item 
instrument (see Appendix) relied on 
validated questions assessing e-cigarette 
awareness and use as well as demo-
graphics, drawn from existing studies 
of tobacco product use, and the time 
estimated to complete the survey ranged 
from three to five minutes.20-23 Measures 
of perceived harm used Likert-scaling 
to assess pharmacists’ opinions and level 
of comfort. Measures of knowledge and 
practices focused on ENDS tracking and 
regulation. To resolve issues of missing 
data, we excluded incomplete surveys. We 
conducted tests of statistical significance 
using contingency tables to understand 
distinguishing characteristics associated 
with California pharmacists’ knowledge 
and attitudes toward ENDS. 
Results 
Although the sample was self-selected, 
general characteristics of the study were 
representative of California pharmacists. 
A total of 336 surveys were received; 81 
(24%) of these surveys were incomplete 
and removed from the analysis. Results 
are reported from the remaining 255 
(76%) completed surveys. The sample 
was compared to population data on the 
total numbers of California pharmacists 
(although the totals differed by source, 
ranging from 28,300 to 35,526).24 Demo-
graphic data of this sample, relative to 
the population of California pharmacists, 
is provided in Table 1; no statistically 
significant differences were identified.
Original Research
Table 1. Comparison of Characteristics of Pharmacy Survey Respondents (n=255) 
to the General Population of California Pharmacists
Characteristic Respondent characteristics, N (%) Population characteristics, N (%)
Gender
Female 154 (60) 20,772 (58)
Male 101 (40) 14,754 (42)
Age
18-44 y 159 (62) 17,978 (51)
45-64 y 62 (24) 12,230 (34)
65+ y 34 (13) 5,316 (15)
Unknown 2 (<1)
Time in practice
<5 years 92 (36) No data
5-10 years 42 (16) No data
>10 years 121 (47) No data
Practice setting
Hospital 96 (38) 9,622 (34)
Ambulatory care 42 (16) 3,679 (13)
Community 61 (24) 13,018 (46)
Other (self-report) 56 (22) 1,981 (7)
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Knowledge
Respondents were asked if they believed 
that the FDA was regulating ENDS. 
Most respondents (60%, n=152) were 
aware that the FDA was not regulating 
the use and safety of ENDS at the time 
of the survey. The remaining respon-
dents either believed that the FDA was 
regulating at the time of the survey 
(23%) or were unaware of ENDS’ regula-
tory status (17%). Results are shown in 
Figure 1. This awareness did not appear 
to be associated with general experience 
or with exposure to ENDS; no significant 
correlations were found between knowl-
edge of ENDS regulatory status and years 
in practice (P=0.07, χ2=8.51), working in 
a practice that tracked nicotine product 
use (P=0.43, χ2=3.84), or practice setting 
(P=0.87; χ2=2.41).
Perceptions of Health Risks
At the time of the survey, studies 
assessing the health risks of ENDS 
demonstrated mixed results. Nonetheless, 
most pharmacists surveyed had drawn 
conclusions about their effects. Nearly 9 
in 10 respondents (88%, n=222) reported 
opinions regarding the health risks of 
ENDS relative to combustible cigarettes, 
and 82% (n=208) reported opinions 
about the health risks of exposure to 
secondhand aerosol from ENDS. 
There was widespread agreement 
regarding the addictiveness of ENDS; 
224/255 (88%) respondents believed that 
ENDS were just as addictive as cigarettes 
(see Figure 2). There was less agreement 
about the potential harms of ENDS use; 
only half of the respondents viewed 
ENDS and combustible cigarettes as 
equally harmful (49%, n=126), while a 
quarter (26%, n=65) viewed ENDS as less 
harmful (see Figure 3). Nearly all phar-
macists who perceived that ENDS were 
more harmful than cigarettes (n=31) also 
believed that ENDS were as addictive as 
cigarettes (93%, n=29). 
Respondents reported a range of percep-
tions regarding the risks of secondhand 
ENDS aerosol exposure. Only 3% stated 
that secondhand ENDS aerosol was “not 
harmful,” while 39% stated that it was 
“less harmful” than secondhand smoke. 
Another 37% of respondents stated that 
secondhand ENDS aerosol and second-
hand smoke were “equally” harmful, and 
3% of respondents stated that secondhand 
ENDS aerosol was “more harmful.” The 
remaining 18% of respondents stated that 
they did not know whether ENDS vapor 
was harmful to non-users. 
Years in practice (P=0.09, χ2=13.81) and 
knowledge of FDA regulation (P=0.59, 
χ2=4.62) had no significant influence on 
perception of ENDS harmfulness rela-
tive to combustible cigarettes. However, 
working in a non-community practice 
Table 2. ENDS Knowledge and Perceptions (Reported as Percentages)
Agree/Yes Disagree/No Don't know
Does using ENDS help people quit smoking? 20 46 34
Are ENDS regulated by the FDA? 23 60 17
ENDS are just as addictive as cigarettes 87 4 8
Note: Data drawn from 2016 California pharmacist survey (N=255).
Table 3. Perceptions of Health Risks for ENDS and Combustible Cigarettes  
(Reported as Percentages)
Is using ENDS less harmful, about  
the same, or more harmful than 
smoking cigarettes?
Do you think the vapor from other 
people's ENDS is harmful to you?
Not harmful – 3
Less harmful than cigarettes 26 39
About the same/equal to 
cigarettes
49 37
More harmful than cigarettes 12 3
Don't know 13 18
Note: Data drawn from 2016 California pharmacist survey (N=255).
FDA, Food and Drug Administration.
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setting was associated with the belief 
that the health risks of using ENDS were 
comparable to combustible cigarettes 
(P=0.01, χ2=26.59).
Smoking Cessation Practices 
Respondents were asked whether they 
assessed smoking behavior, offered 
smoking cessation services for smokers 
and/or ENDS users, felt comfortable 
providing smoking cessation counseling, 
and tracked smoking behavior in patient 
medical records in their practices. 
Most respondents did not consistently 
assess smoking behavior. Overall, few 
pharmacists reported that they always 
(17%, n=42) or often (20%, n=51) asked 
patients about their smoking status; 
nearly two-thirds only sometimes (35%, 
n=90) or never (28%, n=72) asked 
patients if they smoked (see Table 4). 
Asking patients about their smoking 
status was significantly correlated with 
practice setting (P=0.01, χ2=40.8); while 
45% of inpatient pharmacists reported 
that they never asked about smoking 
status, only 18% of managed care 
pharmacists and 21% of community prac-
tice pharmacists reported never asking. 
To assess the possibility that pharmacists 
relied on medical records in lieu of asking 
patients about their smoking status, 
we also asked respondents to report on 
whether their practice tracked tobacco 
use by patients. Most respondents (82%, 
n=209) reported that they had a comput-
erized medical records system at their 
practice. When asked about the tracking 
of tobacco product usage, 36% reported 
that their clinic tracked patients who 
smoked combustible cigarettes, while 10% 
tracked patients who used ENDS. Many 
respondents were not aware whether their 
practice tracked combustible cigarette use 
(30%) or ENDS use (40%) (see Table 5).
With respect to smoking cessation 
counseling, 22% (n=56) always provided 
it, 16% (n=40) often did, 38% (n=96) 
sometimes did, and 25% (n=63) stated 
that they never provided smoking 
cessation counseling. When asked to 
report their confidence about providing 
smoking cessation counselling, only 25% 
Table 4. Smoking Cessation Practices: Tracking (Reported as Percentages)
How often do you ask  
patients if they smoke?
How often do you provide counselling  
for patients who want to quit smoking?
Always do 17 22
Often 20 16
Sometimes 35 38
Never 28 35
Note: Data drawn from 2016 California pharmacist survey (N=255).
Table 5. Tracking of Tobacco Product Use (Reported as Percentages)
Does your clinic currently track  
patients who smoke cigarettes?
Does your clinic currently track  
patients who use ENDS?
Yes 36 10
No 34 59
Don't know 30 40
This study sought 
to assess California 
pharmacists’ awareness 
and approaches 
regarding ENDS to 
gain insight into what 
information is offered 
to patients, and to 
determine whether there 
is a need for continuing 
professional education 
about ENDS targeted  
to pharmacists.
Original Research
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Figure 1 Knowledge and Preceptions of ENDS
Figure 2 Perceptions of Health Risks for ENDS and Combustible Cigarettes
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Table 6. Smoking Cessation Practices: Comfort (Reported as Percentages)
Comfort level on counseling patients 
about smoking cessation
Comfort level on recommending ENDS 
for patients who want to quit
Extremely comfortable 25 4
Somewhat comfortable 49 11
Somewhat uncomfortable 20 37
Extremely uncomfortable 6 48
Note: Data drawn from 2016 California pharmacist survey (N=255).
(n=64) reported that they were extremely 
comfortable counseling on smoking 
cessation, 49% reported they were some-
what comfortable, 20% reported they 
were somewhat uncomfortable, and 6% 
(n=15) reported that they were extremely 
uncomfortable. When asked about 
recommending ENDS for cessation, 
nearly half (48%) stated that they would 
be extremely uncomfortable making this 
recommendation; only 15% said that 
they would be extremely or somewhat 
comfortable making this recommenda-
tion (see Table 6). 
Advice About ENDS  
and Smoking Cessation
Despite inconsistent findings about the 
value of ENDS for cessation at the time 
of the study, 15% (n=39) of respondents 
reported feeling somewhat or extremely 
comfortable recommending ENDS as a 
smoking cessation aid. However, among 
the 39 pharmacists that were comfort-
able recommending ENDS for cessation, 
72% (n=28) perceived them to be just 
as addictive as cigarettes and nearly half 
(46%, n=18) believed that ENDS were 
equally or more harmful than combus-
tible cigarettes.
Discussion
Results indicate that pharmacists gener-
ally had accurate knowledge about the 
regulatory status of ENDS, and their 
advice about cessation reflected national 
guidelines. However, although California 
pharmacists have been encouraged to 
focus on tobacco cessation, only one-
third tracked combustible cigarette use 
by patients and only 10% tracked ENDS 
usage. Counselling for ENDS cessation 
was not reported by pharmacists in any 
practice setting. Although our study 
did not assess the perceived reasons 
for the failure to assess tobacco use or 
counsel for cessation, this could reflect 
system-level factors that interfere with 
pharmacists’ ability to provide smoking 
cessation including time constraints due 
to understaffing or workflow. Further 
research on this question is warranted. 
Pharmacists in our survey expressed little 
enthusiasm for the popular perception of 
ENDS as a reduced-harm product that 
could serve as a smoking cessation aid. 
Our results suggest that expectations 
about ENDS may have mirrored respon-
dents’ understanding of the health risks of 
combustible cigarettes. The overwhelming 
majority of surveyed pharmacists believed 
that ENDS and combustible cigarettes 
were equally addictive, and most believed 
they were equally or more harmful. The 
majority of respondents also believed that 
ENDS users exposed non-users to health 
risks created by secondhand aerosol; 
extensive evidence indicates that exposure 
to secondhand smoke from combustible 
cigarettes is a health risk.1 Consistent 
with these results, few pharmacists felt 
comfortable recommending ENDS for 
patients who wanted to quit smoking. 
We found no correlation between knowl-
edge of FDA regulation and perceptions 
of ENDS risks. Typically the FDA seeks 
to protect the health of the public by 
reviewing the safety and effectiveness 
of products before they are marketed to 
consumers.25 The fact that ENDS were 
marketed without FDA prior approval 
may explain why no correlation was 
observed between knowledge of FDA 
regulation of ENDS and pharmacists’ 
beliefs about the safety of the products. 
Although our study did 
not assess the perceived 
reasons for the failure 
to assess tobacco use or 
counsel for cessation, this 
could reflect system-level 
factors that interfere 
with pharmacists’ ability 
to provide smoking 
cessation including 
time constraints due 
to understaffing or 
workflow. Further 
research on this question 
is warranted. 
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This study has limitations: survey 
respondents may not have accurately 
represented California pharmacists. 
The population of potential respon-
dents involved pharmacists involved in 
professional organizations such as CSHP 
and ASHP; moreover, those who did 
participate may have done so because 
they were more informed about ENDS 
or more concerned about their potential 
health risks. However, findings revealed 
that knowledge about ENDS was limited 
and that pharmacists did not consis-
tently encourage smoking cessation; if 
participants had self-selected for greater 
knowledge, our findings would imply that 
most pharmacists were even less engaged. 
The structure of our survey questions 
may have prompted pharmacists to 
select options that underestimated their 
knowledge; for instance, each institu-
tion could have different protocols about 
whether a technician or pharmacist 
should be the first point of contact in 
interviewing patients and inquiring about 
their smoking status. Even if the patient 
intake workflow in each institution did 
not have a pharmacist as the “primary” 
interviewer, however, it would still be 
their responsibility to review and assess 
smoking status once it was entered into 
the patient's electronic medical record, 
suggesting that low awareness of tobacco 
use is still a problem. Finally, given that 
the study was cross-sectional, it was 
unable to assess possible changes in phar-
macists’ perceptions over time. 
These findings suggest that there is 
widespread agreement among California 
pharmacists about the addictiveness of 
ENDS, which was perceived as compa-
rable to combustible cigarettes, reflecting 
the nicotine in both types of products. 
However, they have not yet developed 
consistent views about the safety of ENDS 
and proposals to use them as a strategy to 
quit combustible cigarette use. Indepen-
dently, pharmacists who responded were 
not consistently assessing tobacco use 
or offering smoking cessation into their 
practices, despite professional and policy 
encouragement. Our results suggest that 
professional organizations may wish to 
provide guidance for pharmacists that 
would address these questions; previous 
work has determined that doing so can 
affect practice.26 Although the pharma-
cists we surveyed were relatively informed 
about the regulatory status of ENDS, 
some advised patients to use ENDS for 
tobacco cessation, contrary to CDC 
recommendations. Continuing educa-
tion addressing new alternative tobacco 
products such as ENDS might improve 
practice in this area. However, the effec-
tiveness of such efforts may be limited by 
structural barriers, including systems that 
do not currently collect data on use. 
Key Points
• Despite encouragement by 
professional associations and policy-
makers, assessing the smoking status 
of patients and providing smoking 
cessation counseling is not yet part 
of most California pharmacists’ 
regular practice.
• California pharmacists were aware of 
the regulatory status of ENDS, their 
addictiveness, and that their use posed 
other health risks.
• Although most respondents were 
aware of the potential health risks 
of ENDS and that they were not 
recommended for cessation, some 
pharmacists advised ENDS use  
as a strategy to quit combustible 
cigarettes.  o
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Definition of E-Cigarettes
We are asking you to take part in a research 
study being done by the CAPSLEAD team at 
the University of California, San Francisco. 
Being in this study is optional. If you choose 
to be in the study, you will complete a survey. 
This survey will help us learn more about 
current pharmacists’ perceptions of electronic 
nicotine delivery systems. The survey will take 
about 3-5 minutes to complete. You can stop 
the survey at any time. The survey is anony-
mous, and no one will be able to link your 
answers back to you. Please do not include 
your name or other information that could be 
used to identify you in the survey responses. 
Questions? Please contact the UCSF CAPS-
LEAD team at CAPSLEAD@listsrv.ucsf.
edu. If you have questions or concerns about 
your rights as a research participant, you can 
call the UCSF Institutional Review Board at 
415-476-1814.
If you want to participate in this study, click 
the Next button to start the survey.
E-cigarettes or Electronic Nicotine Delivery 
Systems (ENDS) can look like regular ciga-
rettes, but are battery-powered and produce 
vapor instead of smoke. ENDS can be bought 
as one-time, disposable products, or as 
re-usable kits with a cartridge. Some people 
refill their own cartridges with nicotine 
fluid, sometimes called “e-juice” or “e-liquid”. 
Disposable ENDS, ENDS cartridges, and 
e-liquid come in many different flavors and 
nicotine concentrations.
Pharmacists Perception of E-Cigarettes
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Cigarette Safety
 Electronic Nicotine Delivery Systems (ENDS)
Q1  Is using ENDS less harmful, about the same, or more harmful than smoking cigarettes?
m Less harmful  (1) 
m About the same  (2) 
m More harmful  (3) 
m Don't know  (4) 
Q2  Do you agree or disagree with the following statement: ENDS are just as addictive as cigarettes?
m Agree  (1) 
m Disagree  (2) 
m Don’t know  (3) 
Q3  Do you think the vapor from other people’s ENDS is harmful to you?
m Not harmful  (1) 
m Less harmful than cigarettes  (2) 
m Equally as harmful as cigarettes  (3) 
m More harmful than cigarettes  (4) 
m Don't know  (5) 
Q4  Do you believe that the United States Food and Drug Administration (FDA) regulates ENDS products in the U.S.?
m Yes  (1) 
m No  (2) 
m Don't know  (3) 
Original Research
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Cessation
Q5 Electronic Nicotine Delivery Systems (ENDS)
Q6 Rate how often you do the following:
Q7  Rate how comfortable you are with the following:
Q8 Using ENDS helps people to quit smoking cigarettes
m Yes  (1) 
m No  (2) 
m Don't know  (3) 
Never (1) Sometimes (2) Often (3) Always (4)
Ask patients if they smoke (1) 
Provide counseling for patients who 
want to quit smoking (2) 
Extremely uncomfortable 
(1)
Somewhat uncomfortable 
(2)
Somewhat comfortable 
 (3)
Extremely comfortable  
(4)
Counseling patients about  
smoking cessation (1) 
Recommending ENDS for your  
patients who want to quit (2) 
Original Research
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Tracking E-Cigarette Usage
 Electronic Nicotine Delivery Systems (ENDS)
Q9 Does your clinic currently track patients who smoke cigarettes (i.e., actively asking and recording their status)?
m Yes  (1) 
m No  (2) 
m Don't know  (3) 
Q10 Does your clinic currently track patients who uses ENDS (i.e., actively asking and recording their status)?
m Yes  (1) 
m No  (2) 
m Don't know  (3) 
Q11 Does your main practice location have a computerized medical records system  
(also known as an electronic health record or an electronic medical record)?
m Yes  (1) 
m No  (2) 
m Don't know  (3) 
Demographics
Q12 Gender:
m Male  (1) 
m Female  (2) 
Q13 Age range:
m 18-44  (1) 
m 45-64  (2) 
m 65+  (3) 
Original Research
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Q14 Race:
m Caucasian  (1) 
m Asian  (2) 
m Black/African American  (3) 
m Hispanic/Latino  (4) 
m Native Hawaiian/Pacific Islander  (5) 
m Two or more races  (6) 
Q15 Main practice setting:
m Hospital Inpatient  (1) 
m Ambulatory Care  (2) 
m Managed Care  (3) 
m Community and Hospital Outpatient  (4) 
m Other  (5) 
Q21 California region of practice: 
m Northern  (1) 
m Central  (2) 
m Southern  (3) 
Q17 Years of pharmacy practice: 
m Less than 5  (1) 
m 5-10  (2) 
m More than 10  (3) 
Original Research
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